Teladoc, Inc. (TDOC) Raised to Hold at BidaskClub
BidaskClub upgraded shares of Teladoc, Inc. (NYSE:TDOC) from a sell rating to a hold rating in a report issued on Wednesday.
Several other analysts have also recently commented on TDOC. Chardan Capital raised their price target on shares of Teladoc from $28.00 to $30.00 and gave the stock a buy rating in a report on Tuesday, May 9th. Robert W. Baird restated a buy rating and set a $28.00 price target on shares of Teladoc in a report on Tuesday, May 9th. Zacks Investment Research upgraded shares of Teladoc from a sell rating to a hold rating in a report on Thursday, May 11th. Craig Hallum cut shares of Teladoc from a buy rating to a hold rating and raised their price target for the stock from $28.00 to $32.00 in a report on Friday, May 12th. Finally, KeyCorp initiated coverage on shares of Teladoc in a report on Wednesday, May 17th. They set an overweight rating and a $37.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $35.55.
Shares of Teladoc (NYSE:TDOC) traded up 3.94% during trading on Wednesday, reaching $33.00. 1,479,161 shares of the company traded hands. Teladoc has a 12 month low of $14.00 and a 12 month high of $36.90. The firm has a 50-day moving average price of $31.87 and a 200-day moving average price of $29.00. The firm’s market capitalization is $1.87 billion.
Teladoc (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.02. The company had revenue of $44.60 million for the quarter, compared to analyst estimates of $44.39 million. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The business’s revenue for the quarter was up 68.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.38) earnings per share. Equities research analysts anticipate that Teladoc will post ($1.44) EPS for the current year.
In related news, insider Adam C. Vandervoort sold 53,806 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $30.92, for a total transaction of $1,663,681.52. Following the transaction, the insider now owns 33,008 shares of the company’s stock, valued at $1,020,607.36. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.47% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the company. ETF Managers Group LLC bought a new position in shares of Teladoc in the second quarter valued at approximately $104,000. Bank of Montreal Can raised its position in shares of Teladoc by 214.2% in the second quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after purchasing an additional 2,397 shares during the period. Pacad Investment Ltd. bought a new position in shares of Teladoc in the second quarter valued at approximately $135,000. Fred Alger Management Inc. bought a new position in shares of Teladoc in the second quarter valued at approximately $139,000. Finally, Great West Life Assurance Co. Can bought a new position in shares of Teladoc in the first quarter valued at approximately $105,000.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.